Pfizer Inc
NYSE:PFE
Pfizer Inc
Narrow
Economic Moat
Pfizer’s moat is narrow: strong proprietary intellectual property and branded franchises plus large-scale manufacturing and entrenched hospital/formulary relationships provide material advantages, but competition, biosimilars, and patent expirations limit a wider moat.
Pfizer Inc
Competitive Advantages
Hospitals and health systems commonly limit stocked biologic brands to a single preferred product and rely on formularies/GPO arrangements, creating institutional inertia and administrative friction that raises switching costs for competing therapies. ([academic.oup.com](https://academic.oup.com/healthaffairsscholar/article/2/6/qxae067/7674343?utm_source=openai))
Extensive patented drugs, vaccine regulatory exclusivities and high-value branded franchises (augmented by acquisitions such as Seagen) sustain pricing power and pipeline value. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Pfizer?utm_source=openai))
A global, large-scale manufacturing and supply network—including multi‑billion‑dose COVID vaccine capacity and expanded CDMO capabilities—gives Pfizer scale advantages for biologics and vaccines that are costly to replicate. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1776985/000177698522000019/bntx-20211231.htm?utm_source=openai))
Wide Economic Moat Companies
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
NVIDIA Corp
NVDA
|
$177.84 |
+0.8%
|
$4.3T | Wide |
|
|
|
Apple Inc
AAPL
|
$256.65 |
+2.1%
|
$3.8T | Wide |
|
|
|
Alphabet Inc
GOOGL
|
$298.63 |
-0.2%
|
$3.6T | Wide |
|
|
|
Microsoft Corp
MSFT
|
$409.48 |
+1.1%
|
$3T | Wide |
|
|
|
Amazon.com Inc
AMZN
|
$213.72 |
+1.6%
|
$2.3T | Wide |
|
|
|
Taiwan Semiconductor Manufacturing Co Ltd
2330
|
NT$1 805 |
+2.4%
|
$1.5T | Wide |
|
|
|
Meta Platforms Inc
META
|
$643.97 |
+0.1%
|
$1.6T | Wide |
|
|
|
Broadcom Inc
AVGO
|
$331.33 |
-1.9%
|
$1.6T | Wide |
|
|
|
Walmart Inc
WMT
|
$123.41 |
+0.6%
|
$983.6B | Wide |
|
|
|
Eli Lilly and Co
LLY
|
$987.42 |
-1.4%
|
$933.5B | Wide |
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
Agilent Technologies Inc
A
|
$115.505 |
+0.1%
|
$32.7B | Wide |
|
|
|
Exelixis Inc
EXEL
|
$41.2 |
+2.2%
|
$11B | Wide |
|
|
|
Halozyme Therapeutics Inc
HALO
|
$67.27 |
-0.3%
|
$7.9B | Wide |
|
|
|
Hamilton Lane Inc
HLNE
|
$106.69 |
+0.9%
|
$6B | Wide |
|
|
|
ADMA Biologics Inc
ADMA
|
$15.37 |
-4.4%
|
$3.7B | Wide |
|
|
|
Catalyst Pharmaceuticals Inc
CPRX
|
$24.13 |
-0.7%
|
$3B | Wide |
|
|
|
Bellring Brands Inc
BRBR
|
$17.38 |
+1.8%
|
$2.1B | Wide |
|
|
|
Rigel Pharmaceuticals Inc
RIGL
|
$28.715 |
-1%
|
$521.2m | Wide |
Pfizer Inc
Glance View
Pfizer Inc., a name synonymous with pharmaceutical innovation, embarked on its journey in 1849 when German immigrants Charles Pfizer and Charles Erhart founded the company in Brooklyn, New York. Over the decades, the modest chemical business transformed into a titan of the pharmaceutical industry, delivering breakthroughs that have shaped modern medicine. The company operates through its robust engine of research and development, continually investing billions into discovering and bringing to market medications that address unmet medical needs. Spanning therapeutic areas such as oncology, vaccines, rare diseases, and cardiovascular and metabolic health, Pfizer's strategic focus ensures a diverse product pipeline that aligns with global health trends and challenges. The company's revenue model is predominantly driven by the development, marketing, and sale of its pharmaceutical products. Blockbuster drugs like Lipitor and recently, the COVID-19 vaccine developed in collaboration with BioNTech, have contributed significantly to its earnings. Pfizer's ability to maintain a strong balance between branded pharmaceuticals and generics allows it to effectively cater to both emerging markets and developed economies, while its strategic partnerships and acquisitions further bolster its reach and capabilities. The synergy of science and business acumen at Pfizer has made it not only a hub of medical innovation but also a formidable enterprise in the competitive landscape of healthcare.
Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.
The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.
Note: This research does not account for survivorship bias. Past performance is not indicative of future results.
Economic Moat
